Sign In To Continue
You have reached the guest article limit.
Unlock more of the IIPLA newsroom by signing in with SSO or joining as a member.
Aptar Pharma has announced the publication of three international patent applications centered on inhaled and nasal delivery of GLP-1-based biologics. Supported by preclinical pharmacokinetic data demonstrating significant improvements in systemic drug exposure, these filings reflect the company’s strategic expansion…
Share This Article
Ready-to-post copy includes the article link.
Aptar Pharma Files New Patents and Reveals Preclinical Advances in Intranasal and Pulmonary GLP-1 Delivery Aptar Pharma has announced the publication of three international patent applications centered on inhaled and nasal delivery of GLP-1-based biologics. Supported by preclinical pharmacokinetic data demonstrating signific... Read the full IIPLA article: https://iipla.org/news/aptar-pharma-files-new-patents-and-reveals-preclinical-advances-in-intranasal-and-pulmonary-glp-1-delivery